• Eli Lilly and Company recently reported second-quarter 2026 results, with revenue rising to about US$23.0 billion and net income to roughly US$7.10 billion, and raised its full-year 2026 revenue outlook to US$85.0 billion–US$87.0 billion.
• At the same time, Lilly is broadening its pipeline and manufacturing base through oncology collaborations, a Breakthrough Therapy designation for KRAS G12C inhibitor olomorasib, and expanded U.S. production capacity for injectable devices used in its diabetes and obesity treatments.
• We’ll now examine how Lilly’s upgraded 2026 revenue guidance and surging incretin demand may reshape the company’s broader investment narrative.

Uncover the next big thing with 20 elite penny stocks that balance risk and reward.

Eli Lilly Investment Narrative Recap

To own Eli Lilly, you need to believe its incretin franchise can support very large, durable cash flows while the pipeline gradually broadens earnings beyond obesity and diabetes. Right now, the most important near term catalyst is management’s upgraded 2026 revenue guidance, which hinges on sustained demand and reliable supply for Mounjaro, Zepbound, and related GLP‑1s. The biggest risk is still concentration in a few flagship drugs, and this quarter’s news reinforces that exposure rather than reducing it.

Among the recent updates, the FDA Breakthrough Therapy designation for olomorasib in KRAS G12C‑mutant pancreatic cancer stands out. It underlines Lilly’s push to balance its obesity and diabetes earnings base with oncology assets that address serious unmet needs. For investors focused on catalysts, progress in olomorasib and the new NSCLC collaboration with Amplia provide a counterweight to GLP‑1 dependence, even as incretins remain the key driver of near term numbers.

Yet despite all the good news, the growing reliance on a handful of incretin products is still something investors should be aware of if...

Eli Lilly's narrative projects $114.2 billion revenue and $46.1 billion earnings by 2029. This requires 16.5% yearly revenue growth and an earnings increase of about $20.8 billion from $25.3 billion today.

Uncover how Eli Lilly's forecasts yield a $1270 fair value, a 7% upside to its current price.

Exploring Other Perspectives

Before this earnings beat, the most optimistic analysts were already modeling Lilly’s revenue reaching about US$124.5 billion and earnings of roughly US$50.0 billion by 2029, which is far above consensus. Compared with the baseline view that emphasizes GLP‑1 concentration risk, this more bullish narrative leans on orforglipron and supply scale as powerful catalysts, and today’s stronger guidance could push those expectations even further, so it is worth weighing both stories side by side.

Explore 19 other fair value estimates on Eli Lilly - why the stock might be worth as much as 39% more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Eli Lilly research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Eli Lilly research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Eli Lilly's overall financial health at a glance.

Ready For A Different Approach?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• The future of work is here. Discover the 36 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.